EUVIMEDEUVIMED entdecken
Leserbrief

GPRC5D-Directed Antibodies in Multiple Myeloma: New Agents and Frontline Strategies From IMS 2026

Changnian Li, Siyuan Cui

Clinical Lymphoma Myeloma and Leukemia · 2026-10

DOI: 10.1016/j.clml.2026.10.017 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-10. Verfasst von Changnian Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China. Die Arbeit nennt 9 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China.
  • Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China. Electronic address: csytcm@126.com.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Li, C., & Cui, S. (2026). GPRC5D-Directed Antibodies in Multiple Myeloma: New Agents and Frontline Strategies From IMS 2026. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2026.10.017

Vancouver

Li C, Cui S. GPRC5D-Directed Antibodies in Multiple Myeloma: New Agents and Frontline Strategies From IMS 2026. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2026.10.017

BibTeX
@article{Li2026,
  author = {Li, Changnian and Cui, Siyuan},
  title = {GPRC5D-Directed Antibodies in Multiple Myeloma: New Agents and Frontline Strategies From IMS 2026},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  doi = {10.1016/j.clml.2026.10.017}
}
Kostenlos starten →